EPICAP Epidémiologie et schémas de traitement du cancer de la prostate métastatique hormonosensible en France, 2018-2023

Objectif(s) de la recherche et intérêt pour la santé publique

Finalité de l'étude

Objectifs poursuivis

Domaines médicaux investigués

Bénéfices attendus

This study will generate information that will contribute to the transparency files submitted to the French National Authority for Health (HAS) in the context of the development of darolutamide. Results will be useful to the health authorities in the context of their evaluation of darolutamide’s clinical benefit as it will allow them to better define the treatment’s position in the therapeutic strategy. It will also improve scientific knowledge of metastatic prostate cancer (mPCa) in France in terms of epidemiology of the disease, therapeutic management, quality of life, social determinant in access to detection and treatment, and factors associated with patient outcomes.
This retrospective longitudinal cohort study will concern all patients with mHSPC in ESND between 2018 and 2023. The main objective of this study is to describe the proportion of patients with mHSPC intensified with a NHT based regimen and exposed to “do not co-administer” pharmacokinetic drug-drug interaction or contra-indication with a comorbidity in France between 2018 and 2023, with a focus on the 2022-23 period.